PPLPHARMA Stock Overview
Operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Piramal Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹217.34 |
| 52 Week High | ₹228.00 |
| 52 Week Low | ₹87.50 |
| Beta | 0 |
| 11 Month Change | 19.73% |
| 3 Month Change | 41.03% |
| 1 Year Change | 106.99% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 14.39% |
Recent News & Updates
Recent updates
Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Jul 14
Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Jun 17We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
May 21It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Shareholder Returns
| PPLPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 11.5% | 0.5% | -1.0% |
| 1Y | 107.0% | 59.3% | 39.5% |
Return vs Industry: PPLPHARMA exceeded the Indian Pharmaceuticals industry which returned 59.3% over the past year.
Return vs Market: PPLPHARMA exceeded the Indian Market which returned 39.5% over the past year.
Price Volatility
| PPLPHARMA volatility | |
|---|---|
| PPLPHARMA Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: PPLPHARMA's share price has been volatile over the past 3 months.
Volatility Over Time: PPLPHARMA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 6,719 | n/a | www.piramalpharma.com |
Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene and protection.
Piramal Pharma Limited Fundamentals Summary
| PPLPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹300.03b |
| Earnings (TTM) | ₹277.60m |
| Revenue (TTM) | ₹83.73b |
1,038x
P/E Ratio3.4x
P/S RatioIs PPLPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPLPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹83.73b |
| Cost of Revenue | ₹33.09b |
| Gross Profit | ₹50.64b |
| Other Expenses | ₹50.36b |
| Earnings | ₹277.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.21 |
| Gross Margin | 60.48% |
| Net Profit Margin | 0.33% |
| Debt/Equity Ratio | 59.5% |
How did PPLPHARMA perform over the long term?
See historical performance and comparison